Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Arvinas, Inc. (NASDAQ:ARVN) have received a consensus recommendation of “Moderate Buy” from the nineteen research firms that are currently covering the firm, Marketbeat reports. Eight research analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $24.09.

A number of research analysts have weighed in on ARVN shares. The Goldman Sachs Group cut their price objective on shares of Arvinas from $12.00 to $8.00 and set a “neutral” rating on the stock in a research report on Friday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arvinas in a research note on Friday, February 7th. Barclays reduced their price target on shares of Arvinas from $32.00 to $16.00 and set an “overweight” rating on the stock in a research note on Friday. Truist Financial reaffirmed a “hold” rating and set a $11.00 target price (down from $21.00) on shares of Arvinas in a research report on Monday. Finally, BMO Capital Markets lowered their price target on shares of Arvinas from $20.00 to $10.00 and set an “outperform” rating for the company in a research report on Monday.

Insider Transactions at Arvinas

In other news, CEO John G. Houston sold 31,338 shares of the firm’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.72, for a total value of $523,971.36. Following the completion of the transaction, the chief executive officer now directly owns 1,157,480 shares in the company, valued at $19,353,065.60. This trade represents a 2.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Ian Taylor sold 9,020 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.71, for a total value of $150,724.20. Following the completion of the sale, the insider now owns 159,121 shares in the company, valued at approximately $2,658,911.91. This represents a 5.36 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 50,230 shares of company stock worth $769,402. Insiders own 5.23% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its position in Arvinas by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 7,062,561 shares of the company’s stock worth $135,389,000 after purchasing an additional 56,561 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Arvinas by 6.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,103,011 shares of the company’s stock worth $78,656,000 after acquiring an additional 249,295 shares during the period. RTW Investments LP raised its position in Arvinas by 19.8% during the fourth quarter. RTW Investments LP now owns 3,334,308 shares of the company’s stock valued at $63,919,000 after acquiring an additional 551,979 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Arvinas by 18.7% in the third quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company’s stock valued at $57,371,000 after acquiring an additional 367,343 shares during the period. Finally, T. Rowe Price Investment Management Inc. acquired a new position in Arvinas in the fourth quarter valued at approximately $42,332,000. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas Trading Down 1.2 %

Shares of NASDAQ ARVN opened at $7.63 on Thursday. The stock has a market capitalization of $556.92 million, a price-to-earnings ratio of -2.75 and a beta of 2.21. Arvinas has a 12-month low of $5.94 and a 12-month high of $37.38. The firm’s 50-day moving average price is $9.47 and its 200-day moving average price is $17.23.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings data on Thursday, May 1st. The company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.93) by $2.07. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. Arvinas’s quarterly revenue was up 646.2% compared to the same quarter last year. During the same period last year, the business posted ($0.97) earnings per share. On average, equities analysts predict that Arvinas will post -3.81 EPS for the current fiscal year.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.